Karolinska Development AB: EU Grants EUR 6 Million to the Clinical Development of Athera Biotechnologies' Cardiovascular Disease Antibody Therapy
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB (STO:KDEV) owns 65% of Athera Biotechnologies AB. Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death. This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.
Help employers find you! Check out all the jobs and post your resume.
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB (STO:KDEV) owns 65% of Athera Biotechnologies AB. Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death. This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.
Help employers find you! Check out all the jobs and post your resume.